Pear Therapeutics, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas, including the first three PDTs with disease treatment claims from the FDA. Pear’s product, reSET®, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear’s third product, Somryst® for the treatment of chronic insomnia, was the first PDT submitted through FDA’s traditional 510(k) pathway while simultaneously reviewed through FDA’s Software Precertification Pilot Program.
Company profile
Ticker
PEARQ, PEARQ
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Thimble Point Acquisition Corp.
SEC CIK
Corporate docs
IRS number
854103092
PEARQ stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
2 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
10 Apr 23
8-K
Termination of a Material Definitive Agreement
7 Apr 23
10-K
2022 FY
Annual report
31 Mar 23
8-K
Pear Therapeutics Announces Process Exploring Strategic Alternatives
17 Mar 23
8-K
Departure of Directors or Certain Officers
24 Feb 23
S-8
Registration of securities for employees
9 Feb 23
EFFECT
Notice of effectiveness
12 Jan 23
424B5
Prospectus supplement for primary offering
10 Jan 23
CORRESP
Correspondence with SEC
6 Jan 23
Latest ownership filings
SC 13D/A
JAZZ Human Performance Opportunity Fund, LP
28 Apr 23
4
SCOTT M ROCKLAGE
12 Apr 23
SC 13D/A
5AM Ventures IV, L.P.
12 Apr 23
4
Ellen Snow
17 Feb 23
4
Erin K. Brenner
17 Feb 23
4
Ronan O'Brien
17 Feb 23
4
Yuri Maricich
17 Feb 23
4
Julia Strandberg
17 Feb 23
4
CHRISTOPHERD T GUIFFRE
17 Feb 23
4
Corey McCann
17 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 48.78 mm | 48.78 mm | 48.78 mm | 48.78 mm | 48.78 mm | 48.78 mm |
Cash burn (monthly) | 3.80 mm | 10.10 mm | 9.72 mm | 10.28 mm | 1.25 mm | 6.16 mm |
Cash used (since last report) | 56.78 mm | 151.06 mm | 145.38 mm | 153.74 mm | 18.68 mm | 92.15 mm |
Cash remaining | -8.00 mm | -102.27 mm | -96.59 mm | -104.96 mm | 30.10 mm | -43.37 mm |
Runway (months of cash) | -2.1 | -10.1 | -9.9 | -10.2 | 24.1 | -7.0 |
Institutional ownership, Q2 2023
15.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 2 |
Closed positions | 54 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 215.31 mm |
Total shares | 22.69 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
LJ10 | 11.55 mm | $107.45 mm |
Arboretum Ventures IV | 10.86 mm | $100.99 mm |
Advisory Research | 188.97 k | $208.00 k |
Westchester Capital Management | 63.18 k | $69.00 k |
California State Teachers Retirement System | 25.87 k | $6.60 mm |
5AM Ventures IV | 0.00 | $0.00 |
JAZZ Human Performance Opportunity Fund | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
10 Apr 23 | 5AM Partners IV | Class A Common Stock | Sell | Dispose S | Yes | No | 0.12 | 3,172,769 | 380.73 k | 200,000 |
10 Apr 23 | 5AM Partners IV | Class A Common Stock | Sell | Dispose S | Yes | No | 0.12 | 534,855 | 64.18 k | 0 |
10 Apr 23 | 5AM Partners IV | Class A Common Stock | Sell | Dispose S | Yes | No | 0.12 | 12,836,489 | 1.54 mm | 0 |
15 Feb 23 | Alison Bauerlein | Class A Common Stock | Grant | Acquire A | No | No | 0 | 71,428 | 0.00 | 71,428 |
15 Feb 23 | Shivakumar Rajaraman | Class A Common Stock | Grant | Acquire A | No | No | 0 | 52,380 | 0.00 | 52,380 |
15 Feb 23 | Paul Mango | Class A Common Stock | Grant | Acquire A | No | No | 0 | 52,380 | 0.00 | 52,380 |
15 Feb 23 | Kirthiga Reddy | Class A Common Stock | Grant | Acquire A | No | No | 0 | 61,904 | 0.00 | 61,904 |